Related Experiment Videos
[Catheter-guided thrombolysis in peripheral arterial occlusion]
J S Lindholt1, G Holt, J Sandermann
1Viborg Sygehus, organkirurgisk afdeling, karkirurgisk afsnit, og billeddiagnostisk afdeling. jslindholt@mail.tele.dk
Ugeskrift for Laeger
|January 5, 2002
Summary
Catheter-directed thrombolysis uses enzymes to dissolve blood clots. While beneficial for recent occlusions, evidence is limited, and long-term outcomes and agent selection remain unclear, necessitating careful patient selection.
Area of Science:
- Vascular Surgery
- Interventional Radiology
- Cardiology
Background:
- Catheter-directed thrombolysis involves delivering clot-dissolving enzymes via catheter to occlusions.
- Available agents include non-fibrin-specific (streptokinase, urokinase) and fibrin-specific (tissue plasminogen activators) types.
Purpose of the Study:
- To evaluate the efficacy and optimal use of catheter-directed thrombolysis for vascular occlusions.
- To address the lack of clear recommendations regarding thrombolytic agents and infusion protocols.
Main Methods:
- Review of large randomized trials (TOPAS, STILE) and other studies on intravascular thrombolysis.
- Analysis of available data to assess treatment outcomes and limitations.
Main Results:
- Major trials exhibit significant selection bias, hindering generalizability.
- Incomparable data across studies prevents meta-analysis, leading to inconclusive consensus recommendations.
- Thrombolysis for recent (<14 days) occlusions shows potential benefit, but long-term data and recurrence rates are concerns.
Conclusions:
- Current evidence does not support a definitive recommendation for specific thrombolytic agents or infusion methods.
- Exclusion of preoperative thrombolysis for occlusions >14 days is debatable due to potential benefits in improving blood flow.
- Individualized patient selection is crucial for this promising, yet experimental, treatment approach.